Terms: = Skin cancer AND EGFR, mENA, 1956, ENSG00000146648, P00533, ERBB1, ERBB AND Clinical Outcome
36 results:
1. Combined PD-1, BRAF and MEK inhibition in BRAF
Tian J; Chen JH; Chao SX; Pelka K; Giannakis M; Hess J; Burke K; Jorgji V; Sindurakar P; Braverman J; Mehta A; Oka T; Huang M; Lieb D; Spurrell M; Allen JN; Abrams TA; Clark JW; Enzinger AC; Enzinger PC; Klempner SJ; McCleary NJ; Meyerhardt JA; Ryan DP; Yurgelun MB; Kanter K; Van Seventer EE; Baiev I; Chi G; Jarnagin J; Bradford WB; Wong E; Michel AG; Fetter IJ; Siravegna G; Gemma AJ; Sharpe A; Demehri S; Leary R; Campbell CD; Yilmaz O; Getz GA; Parikh AR; Hacohen N; Corcoran RB
Nat Med; 2023 Feb; 29(2):458-466. PubMed ID: 36702949
[TBL] [Abstract] [Full Text] [Related]
2. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience.
Boccaccino A; Borelli B; Intini R; Antista M; Bensi M; Rossini D; Passardi A; Tamberi S; Giampieri R; Antonuzzo L; Noto L; Roviello G; Zichi C; Salati M; Puccini A; Noto C; Parisi A; Rihawi K; Persano M; Crespi V; Libertini M; Giordano M; Moretto R; Lonardi S; Cremolini C
ESMO Open; 2022 Jun; 7(3):100506. PubMed ID: 35696748
[TBL] [Abstract] [Full Text] [Related]
3. Loss of Tpl2 activates compensatory signaling and resistance to egfr/MET dual inhibition in v-RAS transduced keratinocytes.
Kelley MB; Geddes TJ; Ochiai M; Lampl NM; Kothmann WW; Fierstein SR; Kent V; DeCicco-Skinner K
PLoS One; 2022; 17(3):e0266017. PubMed ID: 35325006
[TBL] [Abstract] [Full Text] [Related]
4. Afatinib for the treatment of advanced non-small-cell lung cancer harboring an epidermal growth factor receptor exon 18 E709_T710delinsD mutation: a case report.
Van Acker L; Stevens D; Vermaelen K; Surmont V
J Med Case Rep; 2021 Nov; 15(1):562. PubMed ID: 34809713
[TBL] [Abstract] [Full Text] [Related]
5. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
Tian M; Yang J; Han J; He J; Liao W
Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
[TBL] [Abstract] [Full Text] [Related]
6. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or egfr-TKIs: A pooled analysis.
Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
[TBL] [Abstract] [Full Text] [Related]
7. Associations between skin rash, treatment outcome, and single nucleotide polymorphisms in head and neck cancer patients receiving the egfr-inhibitor zalutumumab: results from the DAHANCA 19 trial.
Brøndum L; Alsner J; Sørensen BS; Maare C; Johansen J; Primdahl H; Evensen JF; Kristensen CA; Andersen LJ; Overgaard J; Eriksen JG
Acta Oncol; 2018 Sep; 57(9):1159-1164. PubMed ID: 29771169
[TBL] [Abstract] [Full Text] [Related]
8. Impact of dermatologic adverse reactions on QOL in oncologic patients: results from a single-center prospective study.
Barbu MA; Niţipir C; Voiosu T; Giurcăneanu C
Rom J Intern Med; 2018 Jun; 56(2):96-101. PubMed ID: 29360630
[TBL] [Abstract] [Full Text] [Related]
9. Tracking the Evolution of Non-Small-Cell Lung cancer.
Jamal-Hanjani M; Wilson GA; McGranahan N; Birkbak NJ; Watkins TBK; Veeriah S; Shafi S; Johnson DH; Mitter R; Rosenthal R; Salm M; Horswell S; Escudero M; Matthews N; Rowan A; Chambers T; Moore DA; Turajlic S; Xu H; Lee SM; Forster MD; Ahmad T; Hiley CT; Abbosh C; Falzon M; Borg E; Marafioti T; Lawrence D; Hayward M; Kolvekar S; Panagiotopoulos N; Janes SM; Thakrar R; Ahmed A; Blackhall F; Summers Y; Shah R; Joseph L; Quinn AM; Crosbie PA; Naidu B; Middleton G; Langman G; Trotter S; Nicolson M; Remmen H; Kerr K; Chetty M; Gomersall L; Fennell DA; Nakas A; Rathinam S; Anand G; Khan S; Russell P; Ezhil V; Ismail B; Irvin-Sellers M; Prakash V; Lester JF; Kornaszewska M; Attanoos R; Adams H; Davies H; Dentro S; Taniere P; O'Sullivan B; Lowe HL; Hartley JA; Iles N; Bell H; Ngai Y; Shaw JA; Herrero J; Szallasi Z; Schwarz RF; Stewart A; Quezada SA; Le Quesne J; Van Loo P; Dive C; Hackshaw A; Swanton C;
N Engl J Med; 2017 Jun; 376(22):2109-2121. PubMed ID: 28445112
[TBL] [Abstract] [Full Text] [Related]
10. On-treatment markers as predictors to guide anti-egfr MoAb treatment in metastatic colorectal cancer: a systematic review with meta-analysis.
Hu J; Zhang Z; Zheng R; Cheng L; Yang M; Li L; Liu B; Qian X
Cancer Chemother Pharmacol; 2017 Feb; 79(2):275-285. PubMed ID: 27878357
[TBL] [Abstract] [Full Text] [Related]
11. Practical recommendation for rash and diarrhea management in Indian patients treated with tyrosine kinase inhibitors for the treatment of non-small cell lung cancer.
Parikh P; Prabhash K; Naik R; Vaid AK; Goswami C; Rajappa S; Noronha V; Joshi A; Chacko RT; Aggarwal S; Doval DC
Indian J Cancer; 2016; 53(1):87-91. PubMed ID: 27146751
[TBL] [Abstract] [Full Text] [Related]
12. Targeting the epidermal growth factor receptor in solid tumors: focus on safety.
Lucchini E; Pilotto S; Spada E; Melisi D; Bria E; Tortora G
Expert Opin Drug Saf; 2014 May; 13(5):535-49. PubMed ID: 24684184
[TBL] [Abstract] [Full Text] [Related]
13. Is biomarker research advancing in the era of personalized medicine for head and neck cancer?
Yokota T
Int J Clin Oncol; 2014 Apr; 19(2):211-9. PubMed ID: 24442754
[TBL] [Abstract] [Full Text] [Related]
14. Differentiation of irradiation and cetuximab induced skin reactions in patients with locally advanced head and neck cancer undergoing radioimmunotherapy: the HICARE protocol (head and neck cancer: immunochemo and radiotherapy with erbitux) - a multicenter phase IV trial.
Habl G; Potthoff K; Haefner MF; Abdollahi A; Hassel JC; Boller E; Indorf M; Debus J
BMC Cancer; 2013 Jul; 13():345. PubMed ID: 23855804
[TBL] [Abstract] [Full Text] [Related]
15. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract] [Full Text] [Related]
16. Controversies in antiepidermal growth factor receptor therapy in metastatic colorectal cancer.
Woo J; Palmisiano N; Tester W; Leighton JC
Cancer; 2013 Jun; 119(11):1941-50. PubMed ID: 23504768
[TBL] [Abstract] [Full Text] [Related]
17. Phase II trial of modified FOLFOX6 and erlotinib in patients with metastatic or advanced adenocarcinoma of the oesophagus and gastro-oesophageal junction.
Wainberg ZA; Lin LS; DiCarlo B; Dao KM; Patel R; Park DJ; Wang HJ; Elashoff R; Ryba N; Hecht JR
Br J Cancer; 2011 Sep; 105(6):760-5. PubMed ID: 21811258
[TBL] [Abstract] [Full Text] [Related]
18. clinical observation of 73 nasopharyngeal carcinoma patients treated by helical tomotherapy: the China experience.
Ren G; Du L; Ma L; Feng LC; Zhou GX; Qu BL; Xu SP; Xie CB; Ou GM; Li F; Zhang XX; Yang J
Technol Cancer Res Treat; 2011 Jun; 10(3):259-66. PubMed ID: 21517132
[TBL] [Abstract] [Full Text] [Related]
19. Nuclear HER3 is associated with favorable overall survival in uveal melanoma.
Trocmé E; Mougiakakos D; Johansson CC; All-Eriksson C; Economou MA; Larsson O; Seregard S; Kiessling R; Lin Y
Int J Cancer; 2012 Mar; 130(5):1120-7. PubMed ID: 21484789
[TBL] [Abstract] [Full Text] [Related]
20. Immunoglobulin G fragment C receptor polymorphisms and KRAS mutations: are they useful biomarkers of clinical outcome in advanced colorectal cancer treated with anti-egfr-based therapy?
Paez D; Paré L; Espinosa I; Salazar J; del Rio E; Barnadas A; Marcuello E; Baiget M
Cancer Sci; 2010 Sep; 101(9):2048-53. PubMed ID: 20550522
[TBL] [Abstract] [Full Text] [Related]
[Next]
